In patients with chronic myeloid leukemia (CML), long‐term exposure to imatinib mesylate (IM) upregulates miR‐181a and increases YAP levels, ultimately leading to resistance to IM.210. Here, YAP1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.